Reducing the Risk of Breast Cancer Recurrence

Reducing the Risk of Breast Cancer Recurrence More than 215 000 women with breast cancer each year. For many, surgery to remove the tumor, only the first step in the fight against the disease, often with radiation and / or chemotherapy. After that these women should talk to your doctor if you have “adjuvant” drugs to prevent cancer recurrence. Reducing the Risk of Breast Cancer Recurrence.  If recurrence of breast cancer or a woman does not extend to other parts of the body may be at higher risk of dying from the disease. Women whose breast cancer is detected in nearby  lymph nodes at diagnosis and chemotherapy after surgery have a higher risk of relapse of breast cancer were considered.

Reducing the Risk of Breast Cancer Recurrence postmenopausal women

Postmenopausal women with early breast cancer sensitive to hormones have a new option for
hormone therapy as their first operation. Reducing the Risk of Breast Cancer Recurrence The Administration U. S. Food and Drug recently approved Femara ® (letrozole tablets) December 28, 2005, for this type of use. This approval was made on an average of 24 months of treatment. The study is being conducted to determine  the long-term safety and efficacy of Femara. Already a leader in the treatment of breast cancer, Femara is currently the only drug was in a group called aromatase inhibitors approved for use immediately after surgery and after five years of tamoxifen. Femara FDA granted a priority review, a price for drugs that could potentially offer a significant improvement over products currently on the market without notice.

A panel of the American Society of Clinical Oncology, the group leader of the nation
oncologists recommends aromatase inhibitors such as Femara, as part of optimal adjuvant
therapy for this group of women.


Reducing the Risk of Breast Cancer Recurrence that Femara

“One of the greatest fears of women who were due to breast cancer at an early stage cancer
face is treated to return. With Femara, we now have an option that can help this fear since
early may, even in patients who know that given the increased risk of relapse, “said Matthew
Ellis, MD, PhD, FRCP, Director of the breast cancer at Washington University in St. Louis.
In a large clinical trial of postoperative treatment of breast cancer, the researchers
compared the effectiveness of Femara and tamoxifen, another drug prescribed after surgery. Reducing the Risk of Breast Cancer Recurrence Analysis after 26 months showed that Femara reduced the risk of breast cancer again by the 21% reduction achieved by tamoxifen. Patients taking Femara showed a 27 percent reduction in  risk of cancer to other parts of the body.


Reducing the Risk of Breast Cancer Recurrence at next post,,


Tips for healthy living
Discuss treatment options with an oncologist after surgery. Whether you are a five or ten of
their diagnosis, care of your overall health and well-being also reduce the risk of
recurrence of the disease and give you the energy to do things in life, love do.
• Practice good nutrition
• Exercise regularly
• Press a network of
• Take time for yourself


Note: Important Safety Information
Femara ® (letrozole tablets) for adjuvant (post surgery) treatment of postmenopausal women
with breast cancer hormone receptor positive, admitted at an early stage. The benefits of
Femara clinical studies at 24 months of treatment. Monitoring is needed to determine the
long-term safety and efficacy.
Talk to your doctor if you are allergic to Femara or any of its ingredients. You should not
Femara if you are pregnant because it may cause harm to the fetus. You should take Femara
menopausal. Some women reported fatigue and dizziness with Femara. Until you know how it
affects you, use caution before driving or operating machinery. There was an increase in
cholesterol in patients with Femara compared to tamoxifen (5.4% vs 1.2%). Reducing the Risk of Breast Cancer Recurrence.
In the adjuvant setting were the frequency, side effects were generally mild to moderate.
Side effects seen in Femara and tamoxifen are hot flashes compared (33.7% vs 38%), arthralgia
(21.2% vs 13.5%), night sweats (14.1% vs 13.5 %) weight gain (10, 7% vs 12.9%) and nausea
(9.5% vs 10.4%). Other side effects were bone fractures and osteoporosis.

Leave a Reply

Your email address will not be published. Required fields are marked *